High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients

Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance is, however, a major problem. Determinants of rituximab sensitivity are not fully understood, but effect of rituximab are enhanced by antagon...

Descripción completa

Detalles Bibliográficos
Autores principales: Laursen, Maria Bach, Reinholdt, Linn, Schönherz, Anna Amanda, Due, Hanne, Jespersen, Ditte Starberg, Grubach, Lykke, Ettrup, Marianne Schmidt, Røge, Rasmus, Falgreen, Steffen, Sørensen, Suzette, Bødker, Julie Støve, Schmitz, Alexander, Johnsen, Hans E., Bøgsted, Martin, Dybkær, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366826/
https://www.ncbi.nlm.nih.gov/pubmed/30774774
http://dx.doi.org/10.18632/oncotarget.26588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366826/
https://www.ncbi.nlm.nih.gov/pubmed/30774774
http://dx.doi.org/10.18632/oncotarget.26588

Ejemplares similares